Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.

Kurokawa C, Geekiyanage H, Allen C, Iankov I, Schroeder M, Carlson B, Bakken K, Sarkaria J, Ecsedy JA, D'Assoro A, Friday B, Galanis E.

J Neurooncol. 2017 Jan;131(1):41-48. doi: 10.1007/s11060-016-2285-8. Epub 2016 Nov 5.

2.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG.

Oncotarget. 2016 Aug 2;7(31):50290-50301. doi: 10.18632/oncotarget.10366.

3.

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.

Palani S, Patel M, Huck J, Zhang M, Balani SK, Yang J, Chen S, Mettetal J, Manfredi M, Shyu WC, Ecsedy JA, Chakravarty A.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1255-64. doi: 10.1007/s00280-013-2305-8. Epub 2013 Oct 8.

PMID:
24101146
4.

Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.

Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, Lehman NL.

Cancer Res. 2014 Oct 1;74(19):5364-70. doi: 10.1158/0008-5472.CAN-14-0386. Epub 2014 Aug 8.

5.

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.

Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB.

Clin Cancer Res. 2011 Dec 15;17(24):7614-24. doi: 10.1158/1078-0432.CCR-11-1536. Epub 2011 Oct 20.

6.

The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.

Zumbar CT, Usubalieva A, King PD, Li X, Mifsud CS, Dalton HM, Sak M, Urio S, Bryant WM, McElroy JP, Farmer G, Lehman NL.

J Neurooncol. 2018 May;137(3):481-492. doi: 10.1007/s11060-018-2755-2. Epub 2018 Feb 2.

7.

Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.

Zullo KM, Guo Y, Cooke L, Jirau-Serrano X, Mangone M, Scotto L, Amengual JE, Mao Y, Nandakumar R, Cremers S, Duong J, Mahadevan D, O'Connor OA.

Clin Cancer Res. 2015 Sep 15;21(18):4097-109. doi: 10.1158/1078-0432.CCR-15-0033. Epub 2015 Apr 15.

8.
9.

Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.

Iankov ID, Kurokawa CB, D'Assoro AB, Ingle JN, Domingo-Musibay E, Allen C, Crosby CM, Nair AA, Liu MC, Aderca I, Federspiel MJ, Galanis E.

Cancer Gene Ther. 2015 Sep;22(9):438-44. doi: 10.1038/cgt.2015.36. Epub 2015 Aug 14.

10.

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2010 Jul 15;55(1):26-34. doi: 10.1002/pbc.22430.

11.

Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.

Wang-Bishop L, Chen Z, Gomaa A, Lockhart AC, Salaria S, Wang J, Lewis KB, Ecsedy J, Washington K, Beauchamp RD, El-Rifai W.

Gastroenterology. 2019 Feb;156(3):662-675.e7. doi: 10.1053/j.gastro.2018.10.030. Epub 2018 Oct 17.

PMID:
30342037
12.

The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.

Hong X, O'Donnell JP, Salazar CR, Van Brocklyn JR, Barnett KD, Pearl DK, deCarvalho AC, Ecsedy JA, Brown SL, Mikkelsen T, Lehman NL.

Cancer Chemother Pharmacol. 2014 May;73(5):983-90. doi: 10.1007/s00280-014-2430-z. Epub 2014 Mar 14.

13.

Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.

Wang L, Arras J, Katsha A, Hamdan S, Belkhiri A, Ecsedy J, El-Rifai W.

Mol Oncol. 2017 Aug;11(8):981-995. doi: 10.1002/1878-0261.12066. Epub 2017 May 30.

14.

Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.

Qi L, Zhang Y.

Tumour Biol. 2015 Mar;36(3):1797-802. doi: 10.1007/s13277-014-2782-3. Epub 2014 Nov 4.

PMID:
25366143
15.

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, Ecsedy J, Giles FJ, Carew JS.

Int J Cancer. 2012 Dec 1;131(11):2693-703. doi: 10.1002/ijc.27579. Epub 2012 Jun 28.

16.

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.

Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF.

Drug Des Devel Ther. 2015 Jan 14;9:487-508. doi: 10.2147/DDDT.S74127. eCollection 2015.

17.

Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.

Wetmore C, Boyett J, Li S, Lin T, Bendel A, Gajjar A, Orr BA.

Neuro Oncol. 2015 Jun;17(6):882-8. doi: 10.1093/neuonc/nov017. Epub 2015 Feb 16.

18.

Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.

Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Kenmotsu H, Sugino T, Matsumura Y.

Clin Cancer Res. 2010 Jan 15;16(2):521-9. doi: 10.1158/1078-0432.CCR-09-2393. Epub 2010 Jan 12.

19.

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC.

Oncogene. 2014 Jan 30;33(5):539-49. doi: 10.1038/onc.2012.632. Epub 2013 Jan 21.

20.

Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).

Goos JACM, Verbeek J, Geldof AA, Hiemstra AC, van de Wiel MA, Adamzek KA, Delis-Van Diemen PM, Stroud SG, Bradley DP, Meijer GA, Hoekstra OS, Fijneman RJA, Windhorst AD.

Nucl Med Biol. 2016 Jan;43(1):63-72. doi: 10.1016/j.nucmedbio.2015.08.007. Epub 2015 Sep 11.

PMID:
26432753

Supplemental Content

Support Center